Major US Automaker Chooses Mobileye for Hands-Free Driving Tech
Mobileye secures deal with second top-10 automaker for EyeQ6H-powered hands-free highway driving systems across millions of vehicles worldwide.
NOTRELOAD AI
Altimmune Stock Surges on FDA Breakthrough Designation for Liver Disease Treatment
Altimmune shares jump 24% after FDA grants breakthrough therapy designation for pemvidutide, a promising treatment for MASH liver disease showing significant trial results.
Zenas BioPharma Crashes 53% Despite Meeting Trial Goals—Why Investors Aren't Buying It
Zenas BioPharma stock plunges over 50% after Phase 3 obexelimab trial results disappoint Wall Street, despite meeting all endpoints in rare autoimmune disease study.
Neumora Shows Promise with New Alzheimer's Agitation Treatment
Neumora Therapeutics (NMRA) announces positive Phase 1b results for NMRA-511, a new drug candidate showing clinically meaningful improvements in Alzheimer's disease agitation symptoms with favorable safety profile.
Vantage Data Centers and Liberty Energy Team Up for Massive Power Project
Vantage Data Centers partners with Liberty Energy to develop 1 gigawatt of power solutions for AI and cloud data centers across North America over the next five years.
FDA Clears Path for Depression Treatment GH001 to Enter Final Testing Phase
GH Research's (GHRS) experimental depression treatment GH001 gets FDA approval to proceed with clinical trials after lifting of clinical hold, targeting 2026 Phase 3 launch.